We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

BioFire Diagnostics

  Gold BioFire Diagnostics, a subsidiary of bioMérieux SA, offers easy-to-use clinical molecular diagnostic solutions based ... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
04 May 2021 - 07 May 2021
Virtual Venue

Multiplex PCR Panel Evaluated for Diagnosis of Pneumonia

By LabMedica International staff writers
Posted on 28 Jan 2021
Print article
Image: The BioFire FilmArray 2.0 System set the standard for in-house molecular infectious disease testing. It enables simplified test ordering, faster turnaround times, and optimized laboratory workflow (Photo courtesy of BioFire Diagnostics).
Image: The BioFire FilmArray 2.0 System set the standard for in-house molecular infectious disease testing. It enables simplified test ordering, faster turnaround times, and optimized laboratory workflow (Photo courtesy of BioFire Diagnostics).
Population based studies in the USA estimate the incidence of community-acquired pneumonia at 250 cases per 100,000 residents/year. At any given time, 1% of hospitalized patients receive treatment for hospital-acquired pneumonia, rendering pneumonia the most common healthcare-associated infection.

Despite potential benefits of achieving a microbiological diagnosis of pneumonia, including identifying resistant pathogens and decreasing antimicrobial utilization, a number of factors limit the value of traditional diagnostics in clinical practice. Guidelines emphasize the need for rapid, cost-effective and accurate diagnostic tests for pneumonia.

Infectious Disease Specialists at the New York University Grossman School of Medicine (New York, NY, USA) prospectively examined sputum specimens submitted to the microbiology laboratory for bacterial culture. From 5/2019 to 1/2020, the list of submitted specimens was reviewed twice daily. Expectorated, induced and tracheal aspirate specimens were considered for inclusion. The pneumonia panel was performed on high-quality sputum specimens and the results were prospectively compared with sputum cultures and other tests performed per standard of care.

The BioFire FilmArray Pneumonia Panel (BioFire Diagnostics, Salt Lake City, UT, USA) was run within 24 hours of patient selection. A cutoff of ≥105 copies/mL was applied for semiquantitative bacterial assays. The panel detects semi-quantitatively 15 bacterial agents to assist with differentiation between colonization and true infection, and qualitatively three atypical bacterial and eight viral agents. Antimicrobial resistance genes including the methicillin resistance genes mecA/C and MREJ, the carbapenemases KPC, NDM, Oxa-48-like, VIM, IMP and the extended spectrum Beta-lactamase CTX-M are also detected.

The scientists reported that 70 patients were included, 69 of whom completed a 5-day antimicrobial course for pneumonia and 14.3% died during hospitalization. There was a trend of higher rate of microbiologic diagnosis among the patients with culture submitted before antimicrobial administration (9/15 versus 20/55). The panel increased the microbiologic diagnosis from 29/70 to 59/70 patients. The per isolate analysis revealed an increase in the isolation of Haemophilus influenzae and Streptococcus pneumoniae. On review of empiric antimicrobials, there was potential for antimicrobial optimization in 56/70 patients, including nine bacteria among nine patients, not covered by empiric treatment and another 70 antimicrobials in 49 patients that could have been stopped.

The authors observed a significant increase in the rate of microbiologic diagnosis among adult patients hospitalized with pneumonia where the pneumonia panel was used in addition to current standard of care diagnostic methods, together with abundant opportunities for optimization of antimicrobial therapy. The study was published on January 9, 2021 in the International Journal of Infectious Diseases.

Related Links:
New York University Grossman School of Medicine
BioFire Diagnostics

Gold Supplier
SARS-CoV-2 Assay
SARS-CoV-2 Total (COV2T) Assay
COVID-19 Antigen Test (Swab)
Rapid COVID-19 Antigen Test (Swab)
Hematology Analyzer
DxH 560 AL
Preterm Delivery Test (phIGFBP-1)
Actim Partus 1ngeni

Print article
BIOHIT  Healthcare OY


Molecular Diagnostics

view channel
Image: The EZ DNA Methylation-Direct Kit (Photo courtesy of Zymo Research)

Leukocyte Epigenomics and Artificial Intelligence Predict Late-Onset Alzheimer’s Disease

Alzheimer’s Disease (AD) is the most common form of age-related dementia, accounting for 60%–80% of such cases. The disorder causes a wide range of significant mental and physical disabilities, with profound... Read more


view channel
Image: The Novodiag platform combines real-time PCR and microarray capabilities to provide high-level multiplexing (Photo courtesy of Mobidiag Ltd.)

Hologic to Acquire Mobidiag to Strengthen Diagnostic Testing Business

Hologic, Inc. (Marlborough, MA, USA) has signed a definitive agreement to acquire Mobidiag Ltd. (Espoo, Finland) in a USD 795 million transaction that will accelerate the global growth of Mobidiag’s differentiated... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.